Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
02:00pm, Sunday, 08'th Mar 2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin
Investors Purchase High Volume of Xenon Pharmaceuticals Call Options (NASDAQ:XENE)
01:14am, Thursday, 05'th Mar 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 6,053 call options on the company. This is an increase of approx
Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month High After Analyst Upgrade
02:39am, Sunday, 01'st Mar 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) hit a new 52-week high on Friday after Needham and Company LLC raised their price target on the stock from $55.00 to $58.00. Needham and Com
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
10:42am, Friday, 27'th Feb 2026
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 26'th Feb 2026
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications wit
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
05:21pm, Thursday, 19'th Feb 2026
Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the quar
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
01:40am, Thursday, 19'th Feb 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the stock. This is an increase of app
Dow Extends Record Run Amid Software Stock Rebound
12:16pm, Tuesday, 10'th Feb 2026
The Dow tapped a third consecutive record high thanks to a bounce back in software stocks
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)
01:20am, Thursday, 05'th Feb 2026
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors bought 4,063 put options on the company. This represen
3 Biotech Stocks That Could Double In 2026
10:42am, Tuesday, 20'th Jan 2026
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the m
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study
08:46am, Tuesday, 20'th Jan 2026
Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) Innova
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 16'th Jan 2026
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:15pm, Monday, 12'th Jan 2026
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
08:30am, Monday, 12'th Jan 2026
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 05'th Jan 2026
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini
